tbuckley/cabot-search huggingface dataset:
Palpation
Authors: Nancy Fitz-Hugh Meneely
Journal: Annals of Internal Medicine (2002)

Ad Libitum2 April 2002PalpationNancy Fitz-Hugh MeneelyNancy Fitz-Hugh MeneelyChevy Chase, MD 20815Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-7-200204020-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail It's not my fingers haven't told metruths about a summer honeydew,the underside of leavesand warmth retained in the evening's lake.It's not they wouldn't understandthe need to move like whisperingbeneath my daughter's hair,around my husband's mouth.But when I make them probethe complex privacy of my breastinvade its unresisting slideacross the mooring of my bonesmy fingers are clumsy and reckless,carnival seers foretelling my chancesof grief, romance, longevity,declaring tragedy from mere abundanceor hurrying past some grain of truthtoo hard to understand.I'd rather let them gather into comfortunderneath this density of flesh, hold mein ... Author, Article, and Disclosure InformationAffiliations: Chevy Chase, MD 20815Current Author Address: Nancy Fitz-Hugh Meneely, 4423 Walsh Street, Chevy Chase, MD 20815. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 2 April 2002Volume 136, Issue 7Page: 563KeywordsBoneMouth ePublished: 2 April 2002 Issue Published: 2 April 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 681: Methylation biomarkers of cellular response to demethylating drug
Authors: Xuewei Wang, Jean-Pierre Kocher, Zhifu Sun
Journal: Cancer Research (2019)

Abstract DNA methylation plays an import role in both tumorigenesis and therapy resistance. Demethylating drug regimens have shown efficacy in hematological malignancies, and are actively studied for other cancer types. High variability in patients’ responses to these drugs has been observed and highlights the demand to identify predictive biomarkers for these demethylating drugs. In particular, decitabine (latest FDA-approved demethylating drug) demonstrated as the most potent agent and has the best response on hematological cell lines. Two public datasets were collected to identify methylation biomarkers of decitabine. The first one is from Genomics of Drug Sensitivity in Cancer, with methylation data from Illumina 450K array and drug response from cell lines. The other one is a publicly available patient dataset (methylations from RRBS sequencing and decitabine response from clinic). 64900 CpG sites common to the two methylation platforms were used to train machine learning model (Elastic Net), based on the methylation data and decitabine response (AUC) from 108 hematological cell lines in GDSC. 73 CpGs were identified as predictive biomarkers by Elastic Net. The trained model was then used to make predictions on 39 patients (20 responders and 19 non-responders) with their methylation profiles of the same set of CpGs. The predicted response of responder group is indeed better than non-responder group (p-value = 0.0501), indicating the validity of identified methylation biomarkers. The top one CpG identified by Elastic Net resides in the promoter region of gene C20orf85, and is significantly hypermethylated in non-responder group (p-value = 0.0458), suggesting its potential involvement in the resistance to decitabine. Citation Format: Xuewei Wang, Jean-Pierre Kocher, Zhifu Sun. Methylation biomarkers of cellular response to demethylating drug [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 681.
Correction: Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer
Authors: Michael C Jensen, Katherine J Brempelis, Courtney M Cowan, Shannon A Kreuser, Kevin P Labadie, Brooke M Prieskorn, Nicole A P Lieberman, Chibawanye I Ene, Kara W Moyes, Harrison Chinn, Kole R DeGolier, Lisa R Matsumoto, Sara K Daniel, Jason K Yokoyama, Amira D Davis, Virginia J Hoglund, Kimberly S Smythe, Stephanie D Balcaitis, Richard G Ellenbogen, Jean S Campbell, Eric C Holland, Courtney A Crane
Journal: Journal for ImmunoTherapy of Cancer (2020)
Heberden Society: Combined Meeting, September 1980
Authors: H Dixon, M De Silva, B Hazleman, M Hayes, J English, J Chakraborty, D Freeman, M Lloyd, J Fisher, D Smith, G Zaphiropoulos, K Goddard, D Brown, A Mccarthy, E Kirk, G Ebringer, G Rook, G Swana, D Bottazzo, J Swinson, L Zlosnik
Journal: Annals of the Rheumatic Diseases (1982)
白癜风患者血液中的免疫细胞
Journal: British Journal of Dermatology (2020)

我们知道它涉及到称为 T 淋巴细胞的白细胞，“辅助性”和“细胞毒性”T 淋巴细胞之间的平衡非常重要。我们还知道两种特殊的血液化学物质（“细胞因子”），干扰素‐y（IFN‐y）和肿瘤坏死因子‐a（TNF‐a）控制着这种平衡。然而，这些细胞和细胞因子在其他病症下和在健康人身上也会发生，所以我们需要了解更多的详情来开发有针对性的治疗。
Secukinumab: A Review in Ankylosing Spondylitis
Authors: Hannah A. Blair
Journal: Drugs (2019)

Secukinumab (Cosentyx®), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). Subcutaneous secukinumab significantly improved the clinical signs and symptoms of AS versus placebo in three of four phase III trials. The benefits of secukinumab were generally seen regardless of whether patients had or had not received previous tumour necrosis factor (TNF) inhibitor therapy, and were sustained during longer-term (up to 5 years) treatment. Secukinumab was also associated with improvements in spinal mobility, physical function, health-related quality of life and work productivity in some of the trials. In MEASURE 1, secukinumab reduced inflammation in the sacroiliac joint, and slowed radiographic progression. Secukinumab was generally well tolerated during up to 5 years’ treatment; the most commonly reported adverse event was nasopharyngitis. In the minority of patients who developed anti-drug antibodies (ADAs), ADAs did not decrease efficacy or increase adverse events. In conclusion, secukinumab is an effective therapy for TNF inhibitor-naive patients with active AS, and provides a useful treatment option for patients who have an inadequate response to or are intolerant of TNF inhibitors.
Organotin Compounds and Their Use for Insect and Mite Control
Authors: R. C. Hunter
Journal: Environmental Health Perspectives (1976)

A brief overview of biological activity of organotin compounds is given, with emphasis on activity against plant-feeding arthropods. Plictran miticide, containing cyhexatin (tricyclohexylhydroxystannane), the first product to be fully commercialized for control of plant-feeding mites on a broad range of agricultural crops, is used as a model to indicate the chemistry and potential performance, phytotoxicity, residues, limitations on usage, environmental acceptability, and use patterns for products containing similar organotin compounds.
ACS/NIH organ transplant registry. First scientific report
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Computer programs to support clinical decision making
Authors: E. H. Shortliffe
Journal: JAMA (1987)

Computer programs to assist with medical decision making have long been anticipated by physicians with both curiosity and concern. This article summarizes the current status of computer-based medical decision support, the goals of system developers, the reasons for slow progress since the field began almost 30 years ago, and the logistical and scientific challenges that lie ahead. It emphasizes in particular that decision-support programs are intended to serve as tools for trained practitioners who retain ultimate responsibility for determining diagnostic and therapeutic strategies. (<i>JAMA</i>1987;258:61-66)
Mechanism of Action of Toxic Halogenated Aromatics
Authors: Alison E. M. Vickers, Tracy C. Sloop, George W. Lucier
Journal: Environmental Health Perspectives (1985)

TItrachlorodibenzo-p-dioxin (TCDD) and related halogenated aromatic hydrocarbons are a highly toxic class of environmental contaminants, as evidenced by numerous cases of accidental poisonings of human and animal populations and their extreme toxic potency in laboratory animals.The proposed model for the mechanism of action of TCDD and related compounds is analogous to that of the stereoid hormones, which modulate gene expression through a receptor mechanism.In the steroid receptor model, the compound enters the cell cytoplasm where it acts as a specific ligand, binding selectively to a high affinity receptor protein.Bound to the appropriate ligand, the receptor concentrates in the nucleus where its increased association with chromatin leads to altered gene expression.This model has been useful in characterizing the Ah receptor; however, it does not provide a unifying hypothesis for all biochemical and toxic effects associated with exposure to halogenated aromatic hydrocarbons.Several findings suggest that a primary factor in determining TCDD toxicity might be tissue and species specific factors that control the actions of Ah receptor(s) in target tissues.Furthermore, numerous mechanisms might be involved.Clarifying the mechanism(s) for TCDD toxicity would enhance our ability to predict human health consequences to toxic halogenated aromatic hydrocarbons and would provide a more rational basis for risk analysis.
Herbs and heat in Chinese armamentarium
Authors: C. Macek
Journal: JAMA (1984)

In contrast with the centuries-old practice of traditional Chinese medicine, Western medicine was introduced to China less than 200 years ago. And the first Western medical school, St John's University in Shanghai, was established in 1880. Nearly 40 years later, the first formal school of traditional Chinese medicine was established, also in Shanghai. Before then, traditional medicine was taught through apprenticeships. A physician accepted only one student, who spent years learning from his mentor and the classic medical literature. Both types of medical schools still exist in China, although the 123 Western medical schools far outnumber the 24 traditional schools, and some traditional physicians still have apprentices. But distinctions between the two systems of medicine are not as sharp as at the turn of the century. For example, students in traditional schools are required to learn anatomy and physiology, while students trained in Western medicine become familiar with herbal medicines
Safe staffing
Authors: Fiona Godlee
Journal: BMJ (2018)

How many doctors does it take to staff a hospital?This might seem a simple question, but even asking it seems brave some.What if the answer shows how hospitals have safe medical cover?After the scandal of Mid Staffordshire, Robert Francis called on the National Institute for Health and Clinical Excellence to draw up safe staffing levels, to be policed by the Care Quality Commission.NICE has produced guidelines for the number of nurses needed but not for doctors.
'What are my chances of getting breast cancer?'
Authors: T. C. Bernstein
Journal: JAMA (1977)

AT A FORMAL dinner one evening last year, I was seated beside a young woman, a physician, who posed a question because I, an oncologist, should know the answer. "What are my chances of getting breast cancer?" Before I could clear my professorial throat she went on, "Every woman in my mother's family has breast cancer or has died of it, my mother, her mother, my mother's sister, the sister's daughter, my own sister. With a family history like that, what are my chances?" Many women ask that question, wondering to themselves or aloud to their doctor. Who can make a prediction for an individual? We can only answer with statistics and consider the problems of high risk and low risk. <h3>One in Fifteen</h3> In one of every 15 women, breast cancer will develop. Some characteristics are associated with higher incidence. Endocrine cycles of the body modify the size, activity,
The electrocardiograph as a monitor of cardiac function in the operating room
Authors: V. D. Mazzia
Journal: JAMA (1966)

Study of 19 deaths associated with anesthesia during which the electrocardiogram was monitored revealed that, in at least nine of these patients, ECG changes were not ominous during the initial time in which cardiac output was critically depressed. Dissociation between electrical and contractile cardiac function is the physiological mechanism which probably accounted for the above observation. To demonstrate this, the electrical and contractile actions of the heart were experimentally uncoupled in dogs by simultaneous injection of methoxamine hydrochloride and disodium edetate during monitoring of ECG, electroencephalogram, and femoral-artery and left ventricular pressures. The findings showed that the ECG was usually satisfactory for four to six minutes after cardiac output was absent and marked EEG changes had developed. The clinical and laboratory observations emphasize the need for awareness of the inherent limitations of the ECG as a monitor of total cardiac function.
Studies of T- and B-Lymphocytes in Patients With Connective Tissue Diseases
Journal: Journal of Clinical Investigation (1973)

OBSOLESCENCE-FREE, MODULAR DESIGN instruments that pipette, dilute, dispense, read, count.And with greater precision and reproducibility than other comparable instruments.All Micromedic Systems liquid delivery instruments offer: U * Repeatability of 0.5% C.V. or better.* Continuous micrometer volume adjustment from 0 to 100% of pump capacity.Automated Pipetting Station U * Eliminates manual effort in RIA.* Offers exclusive Slurry Dispenser that automates separations using charcoal and other slurries.MS 2 Spectrophotometer A * Twin 17 ul cuvettes.* Two seconds from feed to read.* Stable: drift less than 0.001A per day.* Repeatable: + 0.001 A or better.Automatic Gamma Counter 0 * Eliminates tube handling by using standard MSI racks.* 588-tube capacity.* Multiple-user operation: each of 3 trays can be independently programmed ... even for isotope selection.
THE NATURE OF THE LEISHMAN-DONOVAN BODIES.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical News
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Liothyronine with levodopa in parkinsonism
Authors: A. J. Prange
Journal: JAMA (1971)

<h3>To the Editor.—</h3> Since levodopa treatment of parkinsonism is attended by significant side effects, efforts have been directed at improving its therapeutic efficiency.<sup>1</sup>The simultaneous use of a drug that blocks peripheral decarboxylation of the amino acid has been promising.<sup>2</sup> For the following reasons we entertained the possibility that a small dose of the thyroid hormone, liothyronine sodium, might potentiate the beneficial effects of levodopa. First, this hormone has been shown to potentiate the antidepressant activity of imipramine<sup>3,4</sup>and amitriptyline. While the mechanism of interaction is unproved, it plausibly involves augmentation of central adrenergic processes.<sup>3</sup>Hyperthyroid patients occasionally show a chorea that resembles the chorea seen in patients with parkinsonism after overdosage with levodopa.<sup>5</sup>Hypothyroid infants often show muscle hypertonia, a usual finding in patients with parkinsonism, and treatment with thyroid hormone reduces it.<sup>6</sup> Guided by these observations we treated seven patients with idiopathic parkinsonism with
"HOSPITAL COSTS"
Authors: John E. White
Journal: JAMA (1924)

<h3>To the Editor:</h3> —Dr. Herman Smith's article inThe Journal, January 12, was timely and to the point. However, I feel that the subject is one of such vital interest that a further discussion might lead to a more general desire to reduce increasing cost per day, per patient, for the hospitalization of the sick and injured. It would seem that the combined intelligence and experience of those who have given at least ten years as medical directors or superintendents of such institutions could be used to good advantage in this emergency, which resolves itself into a very grave situation and one which bids fair to endanger the whole future of this field of work in our public life. The reason for suggesting that men with an experience of at least ten years could do much toward solving many of the problems of today is that they have the decided
Exercise Programs for the Elderly
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Economics
Authors: J. M. Eisenberg
Journal: JAMA (1991)

A major theme of health care policy in the 1980s was the revamping of payment to hospitals and physicians in order to reduce medical care costs while improving, or at least maintaining, quality and access. Researchers have studied the responses of hospitals and physicians to these incentives to understand better the underlying principles of provider behavior and to guide future health care policy initiatives. Early studies on the impact of Medicare's diagnosis related groups (DRG)-based prospective payment system (PPS) for US hospitals confirmed that patients are discharged earlier in the course of their illnesses. Patients with problems such as hip fracture receive fewer inpatient services, are discharged with poorer health status, are more often sent to nursing homes, and stay there longer than before the implementation of the PPS in October 1983.<sup>1</sup>Other studies have found that, while fewer inpatient services are provided during the entire hospitalization since the
Holistic medicine
Authors: G. A. Uhlich
Journal: JAMA (1979)

<h3>To the Editor.—</h3> The editorial "Holistic Health or Holistic Hoax?" once again brings to mind a pet peeve—a grievance that for some reason our profession has not seen fit to voice loud and clear. It is this: Where in the name of everything holy does it say that a physician is to be more than a healer of sickness? And why have we as a profession allowed ourselves to be placed in such a defensive posture when "accused" of limiting our activities to attempting to diagnose and treat illness? Lord knows it is a worthwhile cause, a most difficult and demanding task, and an honorable living. Why in the world are we expected to be all things to all people and take care of all of everyone's problems? And why, worst of all, do we as a profession go about in sackcloth and ashes, beating our breast, and crying "mea
Cervical Cancer
Journal: Journal of the National Comprehensive Cancer Network (2008)

An estimated 11,150 new cases of cervical cancer will be diagnosed in the United States in 2007; 3670 deaths are expected from the disease. Although cervical cancer rates are decreasing among women in the United States, it remains a major world health problem. It is the third most common cancer in women worldwide, with 78% of cases occurring in developing countries. Because persistent human papillomavirus (HPV) infection is considered the most important factor contributing to the development of cervical cancer, immunization against HPV is expected to prevent some cancer. The NCCN Clinical Practice Guidelines in Oncology discuss this and other epidemiologic risk factors, as well as treatment options. For the most recent version of the guidelines, please visit NCCN.org